H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the best growth stocks to invest in for the next 5 years. Analysts at H.C. Wainwright have reaffirmed their $10.00 price target on Aquestive Therapeutics, Inc. (NASDAQ:AQST) while maintaining a Buy rating. This positive outlook follows the approval of a New Drug Application for Anaphylm by the U.S. Food and Drug Administration.
Earlier last week, Anaphylm, a leading non-device-based epinephrine product candidate for immediate treatment of severe allergic reactions, was accepted for review. The FDA has set a Prescription Drug User Fee Act date for January 31, 2026. Wallet portability, rapid onset, and high patient preference are among the many benefits provided by the leading drug that is well-positioned to secure a market share of $2 billion.
A pharmacist showing a patient a green sublingual film formulation with buprenorphine and naloxone.
According to the management, Anaphylm has shown clinical outcomes on par with autoinjectors like EpiPen and Auvi-Q. Its sublingual administration is what sets it apart from nasal spray-based epinephrine products.
Aquestive Therapeutics, Inc. (NASDAQ:AQST), headquartered in New Jersey, is a pharmaceutical company that develops and markets solutions to address unmet medical needs. Incorporated in 2004, the company uses innovative drug delivery technologies like PharmFilm and Adrenaverse.
While we acknowledge the potential of AQST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Content Original Link:
" target="_blank">
